Background: Chromogranin A is a useful tumor marker for neuroendocrine tumors (NETs) diagnosis & follow-up. Octreotide (somatostatin-long acting repeatable (SAS-LAR)) is an established treatment for NETs. Studies regarding the relation between response to SAS-LAR & the change in Chromogranin A (CgA) plasma level are still lacking. Objectives: To determine the association between the u... https://foldlyers.shop/product-category/logic-ics/